GEN Exclusives

More »

GEN News Highlights

More »
Jul 17, 2007

Quidel In-Licenses Flu Antiviral Resistance and Detection Tool

  • Quidel gained exclusive, worldwide rights to the antiviral resistance microarray-based influenza detection technology (AVR-Chip) and the microarray-based influenza B detection technology (BChip) from the University of Colorado at Boulder (CU-Boulder).

    "Exclusive access to molecular-based technologies for influenza B diagnostics and for detection of antiviral resistance, greatly complements our ongoing progress with our MChip technology for influenza A, which was licensed in December 2006 from CU-Boulder, " states Caren Mason, president and CEO.

    The AVR-Chip can identify mutations that may confer resistance to antiviral reagents and may then facilitate proper influenza treatment decisions. The BChip can detect influenza B virus strains. In a study of 62 influenza B virus samples from 19 countries, dating from 1945 to 2005, as well as five negative control samples, the BChip exhibited 97% sensitivity and 100% specificity with no false positives, according to Quidel.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?